Answers are grounded in this paper and cite their sources.
Retrospective cohort study evaluates oral antivirals reducing adverse outcomes in asthmatic patients, suggesting promising treatment options.
Preventing the progression of coronavirus disease 2019 (COVID-19) is a critical issue, particularly in patients with comorbidities such as asthma. However, real-world data on the effectiveness of oral antivirals in patients with asthma and non-severe COVID-19 are limited. This study was conducted to evaluate the effectiveness of 2 oral antivirals, nirmatrelvir/ritonavir (NMV-r) and molnupiravir, in reducing adverse outcomes in asthmatic patients with non-severe COVID-19. This retrospective cohort study included non-hospitalized adults with asthma who were diagnosed with COVID-19 between January 1, 2022, and March 16, 2024, using data from the TriNetX Research Network. The study group received NMV-r or molnupiravir; the control group received no antivirals. Covariates were balanced between the groups using propensity score matching. The primary outcome was the composite incidence of all-cause mortality, all-cause hospitalization, and mechanical ventilation use within 30 days. After matching, each group comprised 19,235 patients. The study group showed significantly lower composite primary outcome (hazard ratio [HR]: 0.57; 95% confidence interval [CI]: 0.49–0.66). Specifically, the study group was associated with significantly lower risk of all-cause hospitalization (HR: 0.59; 95% CI: 0.50–0.69) and all-cause mortality (HR: 0.34; 95% CI: 0.16–0.73) and mechanical ventilation requirements (HR: 0.08; 95% CI: 0.01–0.58). Significantly risk reduction was also observed in subgroups including both sexes, different ages, those with hypertension, dyslipidemia, diabetes mellitus, those receiving NMV-r, and those who had received less than 1 dose and more than 3 doses of vaccine. Our findings suggest oral antivirals, particularly NMV-r, reduce adverse outcomes in asthmatic patients with non-severe COVID-19.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: